ASH: In next BCMA myeloma race, Gracell dazzles with 100% response rate as Pfizer, BMS...

cafead

Administrator
Staff member
  • cafead   Dec 12, 2022 at 11:12: AM
via Five years after Legend Biotech made a splash with an initial 100% tumor response rate for what would later become Johnson & Johnson-partnered Carvykti, another Chinese company has repeated the same remarkable data for its BCMA-targeted CAR-T therapy, this time in an earlier multiple myeloma setting.

article source